Skip to content
Screener

Operating Income at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$663M-24.8%
Stryker logo
StrykerSYK
$1.66B+49.1%
Sanara MedTech Inc. logo
Sanara MedTech Inc.SMTI
$2.65M+221%
Axogen logo
AxogenAXGN
-$2.16M-229%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$8.48M-37.6%
MiMedx Group logo
MiMedx GroupMDXG
-$18.47M-249%

Segments

By segment

See full
Specialty Surgery$88.87M
Tissue Reconstruction$18.94M

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.33B+38.0%
Enterprise value$3.08B+16.2%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Intangible asset amortization3,7703,7547,5467,458
Goodwill impairment charge511,365511,365
Total costs and expenses399,476928,279779,9241,326,429
Operating income (loss)19,285(512,674)30,755(528,171)
Interest income4,2674,7108,3729,130
Interest expense(22,994)(21,042)(45,459)(39,857)
Other income (expense), net4,186(1,946)8,665(2,090)
Income (loss) before income taxes4,744(530,952)2,333(560,988)

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's operating income?
Integra LifeSciences (IART) reported operating income of $19.29M in Q2 2026.
How has Integra LifeSciences's operating income changed year-over-year?
Integra LifeSciences's operating income increased by 103.8% year-over-year, from -$512.67M to $19.29M.
What is the long-term trend for Integra LifeSciences's operating income?
Over 4 years (2021 to 2025), Integra LifeSciences's operating income has grown at a 27.2% compound annual growth rate (CAGR), from $197.23M to -$516.41M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Integra LifeSciences's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude